Current Vaccine News and Events | Page 25

Current Vaccine News and Events, Vaccine News Articles.
Sort By: Most Relevant | Most Viewed
Page 25 of 25 | 1000 Results
Clinical trial shows therapeutic HIV vaccination doesn't lead to viral suppression
A randomized, double-blind, placebo-controlled clinical trial found no benefit for a therapeutic HIV vaccine, but could offer researchers much needed insights for future cure efforts. (2017-12-06)

Army-developed Zika vaccine induces strong immune response in three phase 1 studies
Three Phase 1 human clinical trials evaluating an Army-developed Zika purified inactivated virus (ZPIV) vaccine have shown it was safe and well-tolerated in healthy adults and induced a robust immune response. Initial findings from the trials were published today in The Lancet. (2017-12-05)

Good news from trio of phase one Zika vaccine trials
More than 90 percent of study volunteers in the 3 trials who received the investigational vaccine demonstrated an immune response to Zika virus. (2017-12-05)

Discovery of key molecules involved in severe malaria
A research group led by Osaka University found that proteins called RIFIN expressed on erythrocytes infected with Plasmodium falciparum help the parasite to suppress the host immune response, causing severe malaria. These findings are expected to contribute to the development of effective vaccines and therapeutic drugs against malaria. (2017-12-04)

Gene-based Zika vaccine is safe and immunogenic in healthy adults
Results from two Phase 1 clinical trials show an experimental Zika vaccine developed by government scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is safe and induces an immune response in healthy adults. The findings will be published on Dec. 4 in The Lancet. NIAID is currently leading an international effort to evaluate the investigational vaccine in a Phase 2/2b safety and efficacy trial. (2017-12-04)

Trials show inactivated Zika virus vaccine is safe and immunogenic
The investigational Zika purified inactivated virus (ZPIV) vaccine was well-tolerated and induced an immune response in participants, according to initial results from three Phase 1 clinical trials. Scientists at the Walter Reed Army Institute of Research (WRAIR) are developing the vaccine and leading one of the trials. WRAIR also is co-funding the trials with the National Institute of Allergy and Infectious Diseases, part of NIH. The results will appear in The Lancet. (2017-12-04)

Zika vaccine induces robust immune responses in three phase 1 trials
Healthy adults mounted strong immune responses after receiving an investigational whole inactivated Zika virus vaccine, according to interim analyses of three Phase 1, placebo-controlled, double-blind trials conducted at Beth Israel Deaconess Medical Center (BIDMC), Walter Reed Army Institute of Research (WRAIR), and Saint Louis University School of Medicine. The findings were published today in The Lancet. (2017-12-04)

Location, location, location: Immunization delivery site matters
In vaccination, a certain subpopulation of dendritic cells is vital to triggering the body's adaptive immune system, report researchers at the Jackson Laboratory, Yale University and Astra-Zeneca. Their findings have important implications for vaccine delivery, as the usual method, intramuscular injection, is likely not the most effective way to target those dendritic cells. (2017-12-01)

New vaccine technique effectively fights breast cancer in mice
The body's own immune system can effectively fight breast cancer with the help of a new vaccine technique, researchers from the University of Copenhagen show in mice trials. The technique holds great potential if the effect translates to humans, the researchers find. (2017-11-30)

Human vaccines project presents initial findings from first clinical trials
Scientists leading the clinical programs for the Human Vaccines Project reported today high-level outcomes from two concurrent clinical studies aimed at deciphering the components and mechanisms used by the human immune system to prevent and control disease at the World Vaccine and Immunotherapy Congress in San Diego, Calif. The findings from the studies may provide important new insights on human immunity that the Human Vaccines Project will leverage to launch expanded studies in 2018. (2017-11-30)

HPV vaccine is effective, safe 10 years after it's given
A decade of data on hundreds of boys and girls who received the HPV vaccine indicates the vaccine is safe and effective long term in protecting against the most virulent strains of the virus, researchers report. The findings support more widespread and early administration of the HPV vaccine before preadolescents and adolescents are exposed to the nation's most common sexually transmitted infection and the most common cause of cervical cancer, they report in the journal Pediatrics. (2017-11-29)

Fighting the flu, year after year
In a New England Journal of Medicine perspective, experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza in Melbourne discuss how the process of preparing seasonal influenza vaccines in eggs may contribute to their limited effectiveness. The authors offer research strategies that might yield more protective vaccine candidates. (2017-11-29)

Genetic mutation could, if altered, boost flumist vaccine effectiveness, research suggests
Researchers at Johns Hopkins Bloomberg School of Public Health have discovered a genetic mutation in the FluMist intranasal flu vaccine that has the potential to be altered to enhance the vaccine's protective effect. (2017-11-28)

Malaria: Protective antibodies following natural infection
No effective vaccine exists to date against the tropical disease malaria. Scientists from the German Cancer Research Center have now studied how the human immune system responds to natural infection by the malaria parasite. Analyzing individual immune cells, they discovered that the immune system produces antibodies that are protective against the disease in mice. In addition, long-lived memory cells are formed and produce this antibody again if needed. These findings will help develop more specific next-generation vaccines. (2017-11-28)

Meningococcal vaccine could protect against 91 percent of targeted bacterial strains
Up to 91 percent of bacterial strains causing a common type of invasive serogroup B meningococcal disease in children and young adults are likely to be covered by a four-component vaccine called MenB-4C (Bexsero), according to laboratory studies conducted by investigators at the federal Centers for Disease Control and Prevention (CDC) and at GlaxoSmithKline, manufacturers of the vaccine. The work was published this week in mSphere, an open-access journal from the American Society for Microbiology. (2017-11-22)

New findings to help HIV scientists establish 'template' for potent antibodies
New data published today in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. Led by scientists at the International AIDS Vaccine Initiative (IAVI) and The Scripps Research Institute (TSRI), the results offer important insight into a potential AIDS vaccine design. (2017-11-21)

Enterovirus vaccine prevents virus-induced diabetes in a T1D experimental model
Scientists at the University of Tampere (Finland) and the Karolinska Institutet (Sweden) have demonstrated that an enterovirus vaccine can protect against virus-induced diabetes in a mouse model for Type 1 diabetes. (2017-11-20)

Flu vaccine prevents hospitalization in children
Children vaccinated against influenza are significantly less likely to experience serious complications from the virus that could land them in hospital, new research from Public Health Ontario (PHO) and the Institute for Clinical Evaluative Sciences (ICES) has found. (2017-11-17)

A structural clue to attacking malaria's 'Achilles heel'
New research could boost the development of a more potent vaccine against the global killer. (2017-11-16)

Study raises possibility of naturally acquired immunity against Zika virus
Birth defects in babies born infected with Zika virus remain a major health concern. Now, scientists suggest the possibility that some women in high-risk Zika regions may already be protected and not know it. New research in PLOS Pathogens on Nov. 16, performed in mice, shows women who develop symptom-free Zika infections may be able to acquire immunity that would protect them from future infections and their offspring in a future pregnancy. (2017-11-16)

Developing a new vaccination strategy against AIDS
Infection researchers from the German Primate Center (DPZ) -- Leibniz Institute for Primate Research have in cooperation with international colleagues tested a new vaccination strategy against the HIV-related simian immunodeficiency virus (SIV) in rhesus monkeys. For this, the researchers used a vaccine that consisted of two components. (2017-11-15)

UTEP team advances in developing vaccine for cutaneous leishmaniasis
A research team at The University of Texas at El Paso is one step closer to developing an effective human vaccine for cutaneous leishmaniasis. During the team's more than four years of research at UTEP's Border Biomedical Research Center, they discovered a vaccine formulation that resulted in a 96 percent decrease in the lesions caused by the illness and showed an 86 percent protection rate from the disease in mice. (2017-11-15)

A new strategy for prevention of liver cancer development
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective treatments or drugs. However, an unexpected finding made by a team of University of California San Diego School of Medicine researchers sheds light on the development of a new strategy for prevention of liver cancer. (2017-11-14)

Dengue immunity can protect against Zika virus
A study published the Nov. 13, 2017, issue of Nature Communications by La Jolla Institute for Allergy and Immunology (LJI) investigator Sujan Shresta, Ph.D., now addresses interplay between dengue and ZIKV infections. It reports that mice rendered immune to dengue show 'cross-protection' from subsequent Zika infection and then identifies specific types of immune T-cells capable of defending against both viruses. These revelations have profound implications for efforts to build a potent anti-Zika vaccine. (2017-11-13)

Annual influenza vaccination does not prevent natural immunity
Earlier studies have suggested that having repeated annual influenza vaccination can prevent natural immunity to the virus, and potentially increase the susceptibility to influenza illness in the event of a pandemic, or when the vaccine does not 'match' the virus circulating in the community. But now, researchers at the Influenza Center in Bergen have published a study, which concludes that annual influenza vaccination does not increase susceptibility to influenza infection in years of vaccine mismatch. (2017-11-13)

Understanding the Berlin patient's unexpected cure
Researchers have a new way to understand the much-studied Berlin patient's unexpected cure from HIV and improve outcomes of stem cell transplants for patients with other blood-related diseases such as leukemia and sickle-cell disease. A team at Oregon Health & Science University has shown a species of monkey called Mauritian cynomolgus macaques can successfully receive stem cell transplants. (2017-11-10)

HPV vaccine also prevents uncommon childhood respiratory disease, study suggests
The vaccine that protects against cancer-causing types of human papillomavirus (HPV) also prevents an uncommon but incurable childhood respiratory disease, according to a new study published in The Journal of Infectious Diseases. (2017-11-09)

HPV jab means women only need 3 cervical screens in a lifetime
Women may only need three cervical screens in their lifetime if they have been given the human papillomavirus (HPV) vaccine, according to a new study published in the International Journal of Cancer today. (2017-11-09)

Report of highest incidence of GBS in Africa prompts vaccine study from Wits University
Scientists at the University of the Witwatersrand, Johannesburg (Wits) have contributed to the first comprehensive study of Group B Streptococcus (GBS), a bacterium that infects pregnant women and causes stillbirths and severe invasive disease and death in infants. Africa has the highest burden of GBS, with 54% of estimated cases and 65% of stillbirths and infant deaths. Wits researchers have completed the first study of an investigational GBS vaccine for pregnant women. (2017-11-07)

H3N2 mutation in last year's flu vaccine responsible for lowered efficacy
The below average efficacy of last year's influenza vaccine (which was only 20 to 30 percent effective) can be attributed to a mutation in the H3N2 strain, a new study reports. With the mutation, most people receiving the egg-grown vaccine did not have immunity against H3N2 viruses that circulated last year. (2017-11-06)

Web-based social media intervention can positively influence parental vaccine behaviors
Pregnant women who received vaccine information through an interactive website monitored by a clinical expert were more likely to vaccinate their children than those who did not use the web resource, according to a Kaiser Permanente study published today in the journal Pediatrics. (2017-11-05)

Methotrexate drug holiday improves flu vaccine efficacy in rheumatoid arthritis patients
People with RA who stop taking methotrexate treatment for just two weeks after they have a seasonal flu shot can improve the vaccine's efficacy without increasing RA disease activity, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego. (2017-11-04)

In pursuit of a universal flu vaccine
Developing a universal flu vaccine that would protect against all seasonal and pandemic strains of the virus is no easy task, and new research suggests that one of the most promising strategies -- creating a vaccine that targets the 'stalk' of a protein that covers the flu virus -- is a strong one, but isn't completely bulletproof. Researchers found that the stalk of the hemagglutinin protein can vary in response to pressure from the immune system. (2017-11-03)

4-in-1 flu shot may mean lifelong protection against the flu
Scientists with the Nebraska Center for Virology find a vaccine combining centralized ancestral genes from four major influenza strains could be a path toward a universal flu shot. (2017-11-02)

UGA, Sanofi Pasteur develop new broadly protective vaccines for H3N2 influenza
Researchers have developed a vaccine candidate that protects against multiple co-circulating strains of H3N2 influenza isolated over five seasons following testing in mouse and ferret models. (2017-11-02)

Long-term study of Nicaraguan children reveals key window in which...
Adding proof to a longstanding but previously unconfirmed theory about severe dengue in humans, a new study in children from Nicaragua pinpoints a narrow but critical range of antibody level that enhances reaction to the disease the second time around. (2017-11-02)

Strong maternal antibodies for HIV ineffective for protecting infants from HIV
HIV+ mothers who possess a strong neutralizing antibody response may be more likely to pass the virus on to her infant through breast feeding. In addition, infants born to mothers with a strong antibody response are significantly more likely to have a serious illness or death, regardless of whether or not they acquire the virus. (2017-10-31)

How flu shot manufacturing forces influenza to mutate
According to a new study from scientists at The Scripps Research Institute (TSRI), the common practice of growing influenza vaccine components in chicken eggs disrupts the major antibody target site on the virus surface, rendering the flu vaccine less effective in humans. (2017-10-30)

New molecule shows promise in HIV vaccine design
Researchers at the University of Maryland and Duke University have designed a novel protein-sugar vaccine candidate that, in an animal model, stimulated an immune response against sugars that form a protective shield around HIV. The molecule could one day become part of a successful HIV vaccine. (2017-10-27)

For college men, low awareness of HPV risk -- Education may help increase vaccination rate
Male collegiate athletes have high rates of risk factors for infection with the cancer-causing human papillomavirus (HPV), but have low HPV vaccination rates and low awareness of their personal health risks, according to a study in the November issue of The Nurse Practitioner, published by Wolters Kluwer. (2017-10-26)

Page 25 of 25 | 1000 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to